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Abstract
Background: Post-resuscitation care after out-of-hospital cardiac arrest (OHCA) is challenging due to the threat of
organ failure and difficult prognostication. Our aim was to examine whether urine biomarkers could give an early
prediction of acute kidney injury (AKI) and outcome.
Methods: This was a prospective observational study of comatose OHCA patients at Oslo University Hospital Ullevål,
Norway. Risk factors were clinical parameters and biomarkers measured in spot urine (cystatin C, neutrophil
gelatinase-associated lipocalin (NGAL) and the product of tissue inhibitor of metalloproteinase 2 (TIMP-2) and
insulin-like growth factor-binding protein 7 (IGFBP7)) at admission and day 3. Outcome variables were AKI within
3 days using the Kidney Disease Improving Global Outcomes definition, 6-month mortality, and poor neurological
outcome (PNO) defined as cerebral performance category 3–5.
Results: Among 195 included patients (85 % males, mean age 60 years), 88 (45 %) died, 96 (49 %) had PNO, and
88 (45 %) developed AKI. In univariate analysis, increased urine cystatin C and NGAL concentration sampled at
admission and day 3 were independent risk factors for AKI, mortality and PNO. Increased urine TIMP-2 × IGFBP7
levels was associated with AKI only at admission. In multivariate analyses combining clinical parameters and
biomarker concentrations, the area under the receiver operating characteristics curve (AuROC) with 95 % confidence
interval (CI) were 0.774 (0.700–0.848), 0.812 (0.751–0.873), and 0.819 (0.759–0.878) for AKI, mortality and PNO, respectively.
Conclusions: In comatose OHCA patients, urine levels of cystatin C and NGAL at admission and day 3 were
independent risk factors for AKI, 6-month mortality and PNO.
Trial registration: Clinicaltrials.gov NCT01239420. Registered 10 November 2010.
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Background
Out-of-hospital cardiac arrest (OHCA) is a major health
problem, with an incidence rate in Europe of 84 per
100,000 inhabitants per year [1]. Among those admitted
to hospital with return of spontaneous circulation (ROSC),
mortality at 30 days, or to hospital discharge is on average
58 % [1], but with large variations across sites. Due to the
reperfusion injury seen in the post cardiac arrest (CA)
syndrome [2, 3], these patients are disposed to develop
multiple organ failure [4], with acute kidney injury (AKI)
affecting about half of the survivors [5, 6]. Even though
most organ functions recover, some patients suffer long-
time disability with poor neurological outcome (PNO) [7].
A huge challenge for clinicians is the lack of reliable pre-
dictors of AKI, mortality, and neurological outcome after
OHCA. An early diagnostic and/or prognostic biomarker
could potentially optimize targeted post-resuscitation care
and reduce the burden of futile treatment to patients, rela-
tives and the healthcare system [8].
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There are many candidate biomarkers that aim to pre-
dict AKI and prognosis after CA, but none of these have
discriminating power high enough to be recommended
for routine use [9, 10]. Promising biomarkers of AKI are
cystatin C [11], neutrophil gelatinase-associated lipocalin
(NGAL) [12], tissue inhibitor of metalloproteinase 2
(TIMP-2), and insulin-like growth factor-binding protein
7 (IGFBP7) [13]. Recent studies of CA patients revealed
that NGAL measured in blood was a predictor of AKI
[14], mortality [14, 15], and neurological outcome [14].
In one of the studies, enrolment serum NGAL actually
performed better than neuron-specific enolase and S100B
in predicting survival to hospital discharge [14]. However,
we lack data on the diagnostic and prognostic utility of
the AKI biomarkers cystatin C, NGAL, TIMP-2, and
IGFBP7 measured in urine early after OHCA.
The primary aim of this study was to examine the ability
of urine biomarkers to predict AKI, mortality and PNO
after OHCA. The secondary aim was to find the optimal
biomarker and sampling time, and to investigate if the dis-
criminating power was improved in models combining
clinical parameters and biomarker concentrations.
Methods
Study design and setting
Patients were consecutively enrolled in this prospective
study of OHCA patients as an a priori planned substudy
of the yet not published Norwegian Cardiorespiratory
Arrest Study (NORCAST) (NCT01239420). The primary
aim of the NORCAST study was to assess early predictors
of patient outcome after OHCA. Oslo University Hospital
Ullevål is a community hospital for approximately 200,000
people, and a regional hospital for 1.4 million people in
Norway, with around 45,000 admissions per year. The
Regional Committee for Medical Research Ethics of East-
ern and Southern Norway approved the study.
Study population
Adult (≥18 years) comatose (Glasgow Coma Scale ≤8 at
admission) OHCA patients with ROSC admitted between
8 September 2010 and 13 January 2014 were included. Pa-
tients with known chronic kidney disease (CKD), or who
died within 24 h of intensive care unit (ICU) stay, or for
some reason did not receive active treatment, were ex-
cluded. Patients were treated according to our own stand-
ard operating procedure (SOP) for OHCA, including the
use of targeted temperature management (TTM), with
target set at 33 °C for 24 h. Patients were followed in detail
during their hospital stay until an extensive 6-month post-
arrest consultation.
Study definitions
OHCA was defined as the absence of spontaneous respir-
ation in a comatose patient receiving cardiopulmonary
resuscitation (CPR). ROSC was identified as sustained
electrical activity on the electrocardiogram generating a
palpable pulse. AKI and CKD were classified according to
Kidney Disease Improving Global Outcomes (KDIGO)
guidelines [16, 17], but only data from the first 3 days of
ICU stay were assessed. In the definition of AKI the patients’
steady-state creatinine concentrations prior to CA remain
unknown, and we used relative changes from creatinine
levels at admission. The worst of the serum creatinine and
urine output criteria was considered, and all patients under-
going renal replacement therapy (RRT) were classified as
stage 3. PNO was defined as a cerebral performance
category 3–5 [7]. Severity of illness was assessed using
the Simplified Acute Physiology Score (SAPS) II [18], and
the extent of organ failure was considered utilizing the
Sequential Organ Failure Assessment (SOFA) score [19].
Data collection
Baseline characteristics such as age, weight, sex, and prior
medical history were prospectively collected. Traditional
prehospital data following the Utstein criteria [20] were
obtained from the paramedic records and CA registry.
Patient data from the first days was collected from the
ICU charts, including blood sample results from routine la-
boratory investigations, fluid balance (perspiration not in-
cluded), and severity of illness scores (SOFA and SAPS II).
Additional data on mortality and neurological outcome
were obtained during an extensive consultation 6 months
post-arrest.
Biochemical sampling and analyses
Spot urine samples were collected from urine catheters
at admission (0 to 6 h post-arrest) and on day 3 after the
OHCA. Samples were stored in a refrigerator for up to
72 h before being frozen at –70 °C. After thawing, samples
were centrifuged for 5 min at 20 °C and 500 RCF, aliquoted,
and refrozen. Thereafter, the urine samples were re-thawed
and identically re-centrifuged before they were diluted
1:200 and run in duplicate according to the manufac-
turers’ instructions. Cystatin C and NGAL were quantified
using Bio-Plex Pro RBM Human Kidney Toxicity Assays
panel 2 on the Bio-Plex 200 system (Bio-Rad Laboratories,
Hercules, CA, USA). The concentrations of TIMP-2 and
IGFBP7 were measured using the NephroCheck™ Test
(Astute Medical, San Diego, CA, USA), calculating the
product of both biomarker concentrations (TIMP-2 ×
IGFBP7). For all biomarkers, results below the lower
range were set as 0, and results above the upper range
were set as 100,000. A pilot study revealed that the studied
biomarkers in urine were stable when they were stored in
a refrigerator for up to 72 h prior to freezing, and when
centrifuged after thawing [21].
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Statistical methods
Data are presented as number (percentage), median
(interquartile range (IQR)) or mean (standard deviation
(SD)). Univariate analyses were performed using the Pear-
son’s Chi square test and Fisher’s exact test when appro-
priate. The association between potential risk factors and
the outcomes AKI, mortality and PNO were quantified by
odds ratio (OR) with 95 % confidence interval (CI). Vari-
ables with p < 0.25 in the univariate analyses were consid-
ered candidates for the multivariate model if they had less
than 15 % missing data. Independent risk factors were
identified using a multivariate logistic regression model
and a manual backward stepwise elimination procedure.
Multivariate analyses were preceded by estimation of cor-
relation between risk factors. The predictive accuracy of
the models was assessed by calibration and discrimination.
Calibration was evaluated by the Hosmer and Lemeshow
goodness-of-fit test. A statistically non-significant Hosmer
and Lemeshow result (p > 0.05) suggests that the model
predicts accurately on average. Discrimination was evalu-
ated by analysis of the area under the receiver operating
characteristics curve (ROC) curve, and acceptable dis-
criminatory capability was defined as an area under the
ROC curve (AuROC) above 0.7. Chi-square tests for
equality of AuROCs were performed using Stata 14 (Stata-
Corp, College Station, TX, USA); all other statistical ana-
lyses were performed using SPSS 21 for Windows (IBM
SPSS, Chicago, IL, USA). Two-sided p values less than 0.05
were considered statistically significant. Patients with-
out recorded body weight were assumed to be 70 kg if
female and 80 kg if male in the calculation of hourly
urine output. There were some additional missing data
that were handled using only available data.
Results
Patient characteristics and event rates
Of 300 OHCA patients eligible during the study period,
261were included in the NORCAST study. Altogether 66
patients were excluded from this substudy due to differ-
ent reasons (Fig. 1).
In the total cohort of 195 included patients, 165 (85 %)
were male and the mean age was 60 (±14) years. Overall
6-month outcome revealed that 88 (45 %) died and 96
(49 %) had PNO (Table 1). In total, 88 patients (45 %)
developed AKI; 52 (27 %), 23 (12 %), and 13 (7 %) with
stage 1, 2, and 3, respectively. Urine samples were col-
lected from all 195 patients at admission and 164 (84 %)
patients at day 3.
Fig. 1 Flow chart of the study. AKI acute kidney injury, OHCA out-of-hospital cardiac arrest, CA cardiac arrest, CPR cardiopulmonary resuscitation, ICU
intensive care unit, NORCAST Norwegian Cardiorespiratory Arrest Study, PNO poor neurological outcome (defined as cerebral performance category 3–5)
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Risk factors for acute kidney injury
Many possible risk factors for AKI were identified in the
univariate analysis (Table 1). Urine concentrations of
cystatin C, NGAL, and TIMP-2 × IGFBP7 were significantly
higher in patients with AKI compared with patients
without kidney disease both at admission and day 3, ex-
cept for TIMP-2 × IGFBP7 at day 3 (Table 1). Parameters
excluded from the multivariate analysis were time to
ROSC (because of 19 % missing data), as well as bicar-
bonate and lactate concentrations which were strongly
correlated (r > 0.7) to base excess levels (in order to
avoid co-linearity problems). In multiple logistic regres-
sion analysis, urine NGAL levels at day 3 (OR 5.46
(95 % CI 2.65–11.24)), SOFA score at admission day
(OR 2.83 (95 % CI 1.24–6.50)) and serum urea concen-
tration at admission day (OR 2.82 (95 % CI 1.12–4.66))
were independent risk factors for AKI. The Hosmer and
Lemeshow goodness-of-fit test was not significant, indicat-
ing a satisfactory fit of the model (χ2 = 10.48, df = 6, p =
0.11). In the best predictive model, AuROC was 0.774





Risk factor for AKI Crude OR (95 % CI) for AKI p value
Baseline data
Age, years 60.0 ± 13.7 60.2 ± 13.4 Age ≥60 years 0.90 (0.51–1.58) 0.710
Weight, kga (n = 166) 80.0 (75.0–90.0) 85.0 (80.0–94.5) Weight ≥85 kg 1.73 (0.93–3.20) 0.083
Male sex 92 (86.0) 73 (83.0) Female sex 1.26 (0.58–2.75) 0.560
Witnessed CAa (n = 194) 98 (92.5) 71 (80.7) Unwitnessed CA 2.93 (1.20–7.17) 0.015
Bystander CPR 96 (89.7) 75 (85.2) Not bystander CPR 1.51 (0.64–3.57) 0.342
ROSC time, mina (n = 158) 22.0 (15.0–29.0) 30.0 (20.0–42.5) Time to ROSC ≥25 min 2.16 (1.13–4.11) 0.018
Initial VF/VTa (n = 193) 76 (71.0) 52 (59.1) Not initial VF/VT 1.71 (0.93–3.11) 0.081
SAPS II, score 68.2 ± 10.1 73.1 ± 10.3 SAPS II score ≥69 1.92 (1.08–3.42) 0.026
Admission day
Diuresis, L/day 2.26 (1.82–3.28) 1.81 (1.43–2.45) Diuresis <1.93 L/day 3.69 (2.04–6.70) <0.001
Fluid balance, L/day 4.01 (2.79–5.77) 4.74 (3.50–6.30) Fluid balance ≥4.45 L/day 1.49 (0.84–2.62) 0.169
S-Creatinine, μmol/L 94.0 (81.3–105.0) 107.0 (94.0–140.0) S-Creatinine ≥101 μmol/L 5.18 (2.80–9.59) <0.001
S-Urea; mmol/L 6.3 (5.2–7.5) 7.3 (5.8–9.6) S-Urea ≥6.7 mmol/L 2.74 (1.53–4.91) 0.001
B-HCO3
–, mmol/L 20.7 (18.3–22.8) 18.9 (16.4–21.2) B-HCO3
– <19.0 mmol/L 1.95 (1.08–3.52) 0.025
B-BE, mmol/L –5.6 (–9.1 to –3.6) –8.9 (–12.4 to –6.1) B-BE < –7.0 mmol/L 2.68 (1.50–4.80) 0.001
B-Lactate, mmol/L 3.0 (1.7–6.5) 5.2 (2.9–9.3) B-Lactate ≥4.1 mmol/L 1.92 (1.08–3.39) 0.025
SOFA, score 10.0 (9.0–11.0) 11.0 (10.0–12.0) SOFA score ≥10 3.73 (1.84–7.55) <0.001
Urine biomarkers (n = 195 at admission and n = 164 at day 3)
Admission cystatin C, ng/mL 160 (59–440) 639 (155–1871) Admission cystatin C ≥291 ng/mL 3.08 (1.71–5.54) <0.001
Day 3 cystatin C, ng/mLa 45 (17–109) 182 (32–929) Day 3 cystatin C ≥59 ng/mL 3.36 (1.74–6.50) <0.001
Admission NGAL, ng/mL 106 (37–427) 439 (98–1286) Admission NGAL ≥219 ng/mL 3.41 (1.88–6.16) <0.001
Day 3 NGAL, ng/mLa 63 (26–145) 287 (109–903) Day 3 NGAL ≥110 ng/mL 5.65 (2.81–11.30) <0.001
Admission TIMP-2 × IGFBP7 0.25 (0.04–0.85) 0.65 (0.14–2.26) Admission TIMP-2 × IGFBP7≥ 0.36 2.09 (1.18–3.70) 0.012
Day 3 TIMP-2 × IGFBP7a 0.15 (0.06–0.32) 0.24 (0.10–2.49) Day 3 TIMP-2 × IGFBP7≥ 0.18 1.76 (0.93–3.31) 0.079
Outcome
Hospital RRT 0 (0.0) 8 (9.1) Treatment with RRT n.a.
Dead at 6 months 32 (29.9) 56 (63.6) Death n.a.
PNO at 6 months 37 (34.6) 59 (67.0) Poor neurological outcome n.a.
aData from some patients are missing
Categorical data are presented as number (percent), continuous data with skewed distribution as median (interquartile range), and continuous data with normal
distribution or mean (± standard deviation)
Presented p values are from univariate Pearson’s Chi square analysis
AKI acute kidney injury, B whole blood, BE base excess, CA cardiac arrest, CI confidence interval, CPR cardiopulmonary resuscitation, HCO3
– bicarbonate, IGFBP7
insulin-like growth factor-binding protein 7, n.a. not applicable, NGAL neutrophil gelatinase-associated lipocalin, OR odds ratio, PNO poor neurological outcome
defined as cerebral performance category 3–5, ROSC return of spontaneous circulation, RRT renal replacement therapy, S serum, SAPS simplified acute physiology
score, SOFA sequential organ failure assessment, TIMP-2 tissue inhibitor of metalloproteinase 2, VF/VT ventricular fibrillation/ventricular tachycardia
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Table 2 Multivariate analysis of risk factors for acute kidney injury, mortality and unfavourable neurological outcome in resuscitated,
comatose out-of-hospital cardiac arrest patients
Covariates Levels Adjusted OR (95 % CI) p value* AuROC (95 % CI)
with biomarker
AuROC (95 % CI)
without biomarker
p value**
Risk factors for acute kidney injurya
Model I Witnessed CAc No/yes 2.27 (0.85–6.07) 0.104 0.747 (0.667-0.817) 0.719 (0.649-0.790) 0.084
(n = 195) SOFA score day 0 ≥/<10 3.08 (1.46–6.48) 0.003
Urea day 0 ≥/<6.7 mmol/L 2.63 (1.40–4.95) 0.003
Admission cystatin C ≥/<291/ng/mL 2.42 (2.29–4.54) 0.006
Model II Witnessed CAc No/yes 2.15 (0.80–5.77) 0.128 0.752 (0.682-0.821) 0.719 (0.649-0.790 0.046
(n = 195) SOFA score day 0 ≥/<10 2.94 (1.39–6.21) 0.005
Urea day 0 ≥/<6.7 mmol/L 2.63 (1.40–4.95) 0.003
Admission NGAL ≥/<219 ng/mL 2.59 (1.37–4.89) 0.004
Model III SOFA score day 0 ≥/<10 2.76 (1.25–6.10) 0.012 0.725 (0.644-0.806)
(n = 164) Urea day 0 ≥/<6.7 mmol/L 1.98 (1.00–3.93) 0.049
Cystatin C day 3 ≥/<59 ng/mL 2.87 (1.45–5.70) 0.003
Model IV SOFA score day 0 ≥/<10 2.83 (1.24–6.50) 0.014 0.774 (0.700-0.848)
(n = 164) Urea day 0 ≥/<6.7 mmol/L 2.82 (1.12–4.66) 0.024
NGAL day 3 ≥/<110 ng/mL 5.46 (2.65–11.24) <0.001
Risk factors for mortalitya
Model V Initial VT/VFc No/yes 4.70 (2.27–9.74) <0.001 0.811 (0.751-0.872) 0.790 (0.727-0.852) 0.141
(n = 195) AKI within 3 days Yes/no 2.83 (1.40–5.69) 0.004
SOFA sore day 0 ≥/<10 3.40 (1.47–7.88) 0.004
Admission cystatin C ≥/<291 ng/mL 2.88 (1.44–5.77) 0.003
Model VI Initial VT/VFc No/yes 4.11 (1.99–8.53) <0.001 0.812 (0.751-0.873) 0.790 (0.727-0.852) 0.131
(n = 195) AKI within 3 days Yes/no 2.86 (1.43–5.74) 0.003
SOFA sore day 0 ≥/<10 3.28 (1.43–7.50) 0.005
Admission NGAL ≥/<219 ng/mL 2.87 (1.44–5.72) 0.003
Model VII Initial VT/VFc No/yes 3.13 (1.45–6.72) 0.004 0.784 (0.713-0.854)
(n = 164) AKI within 3 days Yes/no 2.44 (1.16–5.13) 0.019
SOFA sore day 0 ≥/<10 2.67 (1.14–6.23) 0.024
Cystatin C day 3 ≥/<59 ng/mL 2.45 (1.17–5.13) 0.018
Model VIII Initial VT/VFc No/yes 3.12 (1.45–6.69) 0.004 0.785 (0.713-0.857)
(n = 164) AKI within 3 days Yes/no 2.06 (0.95–4.47) 0.069
SOFA score day 0 ≥/<10 2.88 (1.22–6.84) 0.016
NGAL day 3 ≥/<110 ng/mL 2.85 (1.32–6.14) 0.008
Risk factors for unfavourable neurological outcomea
Model IX Initial VT/VFc No/yes 5.07 (2.40–10.74) <0.001 0.819 (0.759-0.878) 0.810 (0.750-0.870) 0.264
(n = 195) AKI within 3 days Yes/no 2.67 (1.32–5.40) 0.006
BE day 0 </≥–7 mmol/L 2.07 (1.00–4.26) 0.050
SOFA score day 0 ≥/<10 2.45 (1.08–5.57) 0.032
Admission cystatin C ≥/<291 ng/mL 2.06 (1.00–4.25) 0.050
Model Xb Initial VT/VFc No/yes 4.92 (2.35–10.38) <0.001 0.810 (0.750-0.871)
(n = 195) AKI within 3 days Yes/no 3.03 (1.52–6.02) 0.002
BE day 0 </≥–7 mmol/L 2.56 (1.29–5.09) 0.007
SOFA score day 0 ≥/<10 2.48 (1.11–5.54) 0.027
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(95 % CI 0.700–0.848) indicating a good discriminative
ability between patients with and without AKI (Model IV,
Table 2).
Addition of biomarker measurements to clinical param-
eters significantly increased the discriminating power of
AKI in Model II, but not in Model I (Table 2). Cystatin C
and NGAL levels at day 3 were significantly better to
predict AKI stage 2 or 3 than AKI stage 1 (Additional
file 1). The ability to predict AKI was similar for urine
NGAL and cystatin C concentrations (Additional file 2).
Risk factors for mortality and poor neurological
outcome
Data from univariate analyses revealed many possible
risk factors for mortality and PNO (Table 3 and Table 4).
Urine cystatin C and NGAL levels at admission and day
3 were significantly higher in non-survivors compared
with survivors (Table 3) and in patients with PNO com-
pared with patients who had good neurological outcome
(Table 4). In contrast, urine TIMP-2 × IGFBP7 concentra-
tions were similar for both the considered outcomes at
any time point. Time to ROSC, bicarbonate and lactate
levels were excluded from multiple regression analyses
for the same reasons as in the AKI analysis. Independ-
ent risk factors for mortality in multivariate analysis
were high NGAL concentrations at admission (OR 2.87
(95 % CI 1.44–5.72)), initial non-shockable rhythm (OR
4.11 (95 % CI 1.99–8.53)), presence of AKI (OR 2.86
(95 % CI 1.43–5.74)) and high SOFA score at admission
(OR 3.28 (95 % CI 1.43–7.50)). Independent risk factors
for PNO in the multivariate analysis were high cystatin
C levels at admission (OR 2.06 (95 % CI 1.00–4.25)),
initial non-shockable rhythm (OR 5.07 (95 % CI 2.40–
10.74)), presence of AKI (OR 2.67 (95 % CI 1.32–5.40)),
low base excess levels at admission (OR 2.07 (95 % CI
1.00–4.26)) and high SOFA score at admission (OR 2.45
(95 % CI 1.08–5.57)). The Hosmer and Lemeshow
goodness-of-fit tests were not significant, indicating satis-
factory fit of the model for mortality (χ2 = 4.04, df = 7, p =
0.78) and PNO (χ2 = 5.84, df = 8, p = 0.67). In the best pre-
dictive models, the AuROCs were 0.812 (95 % CI 0.751–
0.873) and 0.819 (95 % CI 0.759–0.878) indicating a good
discriminative ability between survivors and non-survivors
(Model VI, Table 2) in addition to patients with PNO and
good neurological outcome (Model IX, Table 2),
respectively.
Addition of biomarker measurements to clinical pa-
rameters did not significantly increase the discriminating
power of mortality or PNO in Model V, VI, or IX, respect-
ively (Table 2). The ability to predict mortality and PNO
was not statistically different when comparing urine
NGAL and cystatin C concentrations (Additional files 3
and 4).
Discussion
Our main finding in this prospective study on resuscitated
comatose OHCA patients was that the urine concentra-
tions of cystatin C and NGAL sampled at admission and
on day 3 were independent risk factors for AKI, mortality,
and PNO. In contrast, TIMP-2 × IGFBP7 levels only
predicted AKI in urine samples collected at admission.
The discriminating power was not uniformly improved
in models combining biomarker concentrations and clin-
ical parameters. Overall outcome was very good, with
51 % of the patients alive with good neurological outcome
6 months post-arrest.
The biomarkers in serum and urine that aim to predict
AKI and prognosis have many shortcomings that limit
their clinical use [9, 10, 22]. In addition to limited dis-
criminating power they differ in organ specificity and
Table 2 Multivariate analysis of risk factors for acute kidney injury, mortality and unfavourable neurological outcome in resuscitated,
comatose out-of-hospital cardiac arrest patients (Continued)
Model XI Initial VT/VFc No/yes 3.42 (1.58–7.39) 0.002 0.778 (0.707-0.849)
(n = 164) AKI within 3 days Yes/no 2.45 (1.17–5.12) 0.017
BE day 0 </≥–7 mmol/L 2.53 (1.24–5.18) 0.011
Cystatin C day 3 ≥/<59 ng/mL 2.25 (1.09–4.65) 0.029
Model XII Initial VT/VFc No/yes 3.77 (1.69–8.38) 0.001 0.797 (0.729-0.866)
(n = 164) Fluid balance day 0 ≥/<4.45 L/day 2.12 (1.05–4.66) 0.037
Urea day 0 ≥/<6.7 mmol/L 2.13 (1.03–4.43) 0.043
BE day 0 </≥–7 mmol/L 2.21 (1.06–4.62) 0.035
NGAL day 3 ≥/<110 ng/mL 3.41 (1.65–7.06) 0.001
aTIMP-2 × IGFBP7 had p values above 0.05 for predicting acute kidney injury, mortality, and unfavorable neurological outcome at all time points
bNGAL at day 0 had a p value above 0.05 for predicting poor neurological outcome
cData from some patients are missing
Data are from multivariate logistic regression analysis
*p values for the adjusted odds ratio; **p values from comparing the AuROC with and without biomarkers
OR odds ratio, CI confidence interval, AuROC area under the curve in receiver operating characteristics analysis, CA cardiac arrest, SOFA sequential organ failure
assessment, NGAL neutrophil gelatinase-associated lipocalin, VF/VT ventricular fibrillation/ventricular tachycardia, AKI acute kidney injury, BE base excess
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time profile. Cystatin C is produced in all nucleated cells
and may be used as a marker of glomerular filtration
rate [11]. NGAL is expressed in epithelial cells in differ-
ent organs, and is considered an inflammatory mediator
upregulated in tubular injury [12]. TIMP-2 and IGFBP7
are markers of cell cycle arrest [13]; TIMP-2 probably
has kidney-protective properties [13], whereas IGFBP7
may reflect renal haemodynamic alterations [13]. Al-
though their time profiles in urine are not fully clarified,
NGAL and cystatin C are elevated approximately 48 h
prior to the development of the clinical syndrome of AKI,
whereas TIMP-2 and IGFBP7 are thought to predict AKI
developing within 12 h [23].
Among the most predictive biomarkers of AKI
tested in general ICU patients are cystatin C, NGAL,
and TIMP-2 × IGFBP7 measured in blood and/or urine
samples [13, 23–26]. In CA patients, there are limited
data showing that NGAL measured in blood within
4 h after ROSC is a predictor of AKI [15]. It is therefore
not surprising that urine cystatin C, NGAL, and TIMP-









Age, years 59.1 ± 13.1 61.4 ± 14.1 Age ≥60 years 1.37 (0.77–2.41) 0.283
Weight, kga (n = 166) 83.0 (75.0–93.0) 85.0 (75.0–90.0) Weight ≥85 kg 1.35 (0.73–2.51) 0.335
Male sex 94 (87.9) 71 (80.7) Female sex 1.73 (0.79–3.80) 0.167
Witnessed CAa (n = 194) 101 (95.3) 68 (77.3) Unwitnessed CA 5.94 (2.13–16.59) <0.001
Bystander CPR 94 (87.9) 77 (87.5) Not bystander CPR 1.03 (0.44–2.44) 0.941
ROSC time, mina (n = 158) 19.0 (12.0–29.0) 30.0 (23.0–44.0) Time to ROSC ≥25 min 3.28 (1.68–6.40) <0.001
Initial VF/VTa (n = 193) 86 (81.1) 42 (48.3) Not initial VF/VT 4.61 (2.42–8.76) <0.001
SAPS II, score 68.3 ± 10.4 73.0 ± 10.0 SAPS II score ≥69 1.62 (0.91–2.87) 0.099
Admission day
Diuresis, L/day 2.03 (1.75–2.84) 1.81(1.43–2.45) Diuresis <1.93 L/day 1.99 (1.12–3.53) 0.018
Fluid balance, L/day 4.05 (2.37–5.74) 4.75 (3.50–6.39) Fluid balance ≥4.45 L/day 1.92 (1.08–3.39) 0.025
S-Creatinine, μmol/L 98.0 (84.0–114.0) 107.5 (94.3–140.0) S-Creatinine ≥101 μmol/L 1.76 (1.00–3.11) 0.051
S-Urea; mmol/L 6.3 (5.1–7.7) 7.3 (5.8–9.7) S-Urea ≥6.7 mmol/L 1.93 (1.09–3.43) 0.023
B-HCO3
–, mmol/L 20.6 (18.9–22.4) 19.0 (16.6–21.2) B-HCO3
– <19.0 mmol/L 2.82 (1.55–5.14) 0.001
B-BE, mmol/L –5.7 (–8.4 to –3.7) –8.8 (–12.4 to –6.0) B-BE < –7.0 mmol/L 3.51 (1.94–6.35) <0.001
B-Lactate, mmol/L 3.3 (1.7–5.9) 5.2 (2.9–9.3) B-Lactate ≥4.1 mmol/L 2.48 (1.39–4.43) 0.002
SOFA, score 10.0 (8.0–11.0) 11.0 (10.0–12.0) SOFA score ≥10 4.26 (2.07–8.75) <0.001
Urine biomarkers (n = 195 at admission and n = 164 at day 3)
Admission cystatin C, ng/mL 160 (57–417) 639 (167–2421) Admission cystatin C ≥291 ng/mL 3.69 (2.08–6.70) <0.001
Day 3 cystatin C, ng/mLa 42 (18–113) 153 (32–777) Day 3 cystatin C ≥59 ng/mL 3.77 (1.94–7.34) <0.001
Admission NGAL, ng/mL 91 (42–334) 506 (152–1322) Admission NGAL ≥219 ng/mL 4.51 (2.46–8.28) <0.001
Day 3 NGAL, ng/mLa 63 (27–148) 221 (98–843) Day 3 NGAL ≥110 ng/mL 4.43 (2.25–8.69) <0.001
Admission TIMP-2 × IGFBP7 0.28 (0.05–1.03) 0.45 (0.11–2.23) Admission TIMP-2 × IGFBP7≥ 0.36 1.76 (1.00–3.11) 0.051
Day 3 TIMP-2 × IGFBP7 a 0.15 (0.07–0.33) 0.21 (0.10–0.61) Day 3 TIMP-2 × IGFBP7≥ 0.18 1.59 (0.84–2.98) 0.151
Outcome
Hospital RRT 3 (2.8) 5 (5.7) Treatment with RRT 2.09 (0.48–9.01) 0.314
AKI within 3 days 32 (29.9) 56 (63.6) Presence of AKI 4.10 (2.52–7.46) <0.001
PNO at 6 months 8 (7.5) 88 (100.0) Poor neurological outcome n.a.
aData from some patients are missing
Categorical data are presented as number (percent), continuous data with skewed distribution as median (interquartile range), and continuous data with normal
distribution or mean (± standard deviation)
Presented p values are from univariate Pearson’s Chi square analysis
AKI acute kidney injury, B whole blood, BE base excess, CA cardiac arrest, CI confidence interval, CPR cardiopulmonary resuscitation, HCO3
– bicarbonate, IGFBP7
insulin-like growth factor-binding protein 7, n.a. not applicable, NGAL neutrophil gelatinase-associated lipocalin, OR odds ratio, PNO poor neurological outcome
defined as cerebral performance category 3–5, ROSC return of spontaneous circulation, RRT renal replacement therapy, S serum, SAPS simplified acute physiology
score, SOFA sequential organ failure assessment, TIMP-2 tissue inhibitor of metalloproteinase 2, VF/VT ventricular fibrillation/ventricular tachycardia
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2 × IGFBP7 were predictors of AKI in the present study.
The finding that TIMP-2 × IGFBP7 was not significantly
associated with the development of AKI at day 3 is prob-
ably caused by the short half-lives of these markers. Unfor-
tunately, urine cystatin C, NGAL, and TIMP-2 × IGFBP7
levels do not discriminate between CA patients with and
without AKI, thereby limiting their clinical utility. How-
ever, as shown in Additional file 1, our findings that cysta-
tin C and NGAL at day 3 performed better in predicting
moderate to severe AKI (stage 2 or 3) compared with mild
AKI (stage 1) is interesting, since worsened AKI severity is
associated with an increased need for RRT and reduced
survival [27]. Because these biomarkers are good pre-
dictors of severe AKI they might be used to forecast
the need for RRT after CA, as has been shown in gen-
eral ICU patients [25].
The biomarkers cystatin C, NGAL, and TIMP-2 ×
IGFBP7 have been prognostic predictors of both renal
Table 4 Univariate analysis of risk factors for poor neurological outcome in resuscitated, comatose out-of-hospital cardiac arrest
patients
Good neurological
outcome (n = 99)




Age, years 59.2 ± 16.4 61.0 ± 14.7 Age ≥60 years 1.32 (0.75–2.32) 0.339
Weight, kga (n = 166) 83.0 (75.0–93.3) 85.0 (75.0–90.0) Weight ≥85 kg 1.28 (0.69–2.36) 0.428
Male sex 87 (87.9) 78 (81.3) Female sex 1.67 (0.76–3.69) 0.200
Witnessed CAa (n = 194) 94 (95.9) 75 (78.1) Unwitnessed CA 6.58 (2.17–20.00) <0.001
Bystander CPR 86 (86.9) 85 (88.5) Not bystander CPR 0.86 (0.36–2.02) 0.722
ROSC time, mina (n = 158) 22.5 (12.0–29.0) 30.0 (23.0–40.0) Time to ROSC ≥25 min 3.16 (1.63–6.10) 0.001
Initial VF/VTa (n = 193) 82 (83.7) 46 (48.4) Not initial VF/VT 5.46 (2.79–10.67) <0.001
SAPS II, score 67.8 ± 10.4 73.1 ± 9.9 SAPS II score ≥69 2.01 (1.13–3.56) 0.017
Admission day
Diuresis, L/day 2.03 (1.77–2.86) 1.81 (1.43–2.50) Diuresis <1.93 L/day 1.98 (1.12–3.50) 0.018
Fluid balance, L/day 3.97 (2.58–5.64) 4.80 (3.46–6.45) Fluid balance ≥4.45 L/day 2.07 (1.17–3.66) 0.012
S-Creatinine, μmol/L 96.0 (84.0–113.0) 107.5 (94.0–139.3) S-Creatinine ≥101 μmol/L 1.90 (1.08–3.36) 0.026
S-Urea; mmol/L 6.3 (5.3–7.8) 7.1 (5.7–9.6) S-Urea ≥6.7 mmol/L 1.90 (1.08–3.36) 0.026
B-HCO3
–, mmol/L 20.6 (18.9–22.6) 19.0 (17.1–21.2) B-HCO3
– <19.0 mmol/L 2.58 (1.42–4.71) 0.002
B-BE, mmol/L –5.6 (–8.2 to –3.6) –8.5 (–12.0- –6.0) B-BE < –7.0 mmol/L 4.18 (2.30–7.68) <0.001
B-Lactate, mmol/L 2.8 (1.6–5.4) 5.1 (3.1–9.1) B-Lactate ≥4.1 mmol/L 2.68 (1.50–4.77) 0.001
SOFA, score 10.0 (9.0–11.0) 11.0 (10.0–12.0) SOFA score ≥10 3.66 (1.85–7.24) <0.001
Urine biomarkers (n = 195 at admission and n = 164 at day 3)
Admission cystatin C, ng/mL 166 (55–411) 612 (141–2420) Admission cystatin C ≥291 ng/mL 3.33 (1.85–6.00) <0.001
Day 3 cystatin C, ng/mLa 45 (17–113) 137 (32–595) Day 3 cystatin C ≥59 ng/mL 3.22 (1.69–6.13) <0.001
Admission NGAL, ng/mL 91 (42–315) 497 (144–1286) Admission NGAL ≥219 ng/mL 4.01 (2.21–7.27) <0.001
Day 3 NGAL, ng/mLa 61 (26–146) 213 (95–755) Day 3 NGAL ≥110 ng/mL 4.21 (2.18–8.12) <0.001
Admission TIMP-2 × IGFBP7 0.25 (0.04–1.03) 0.43 (0.12–2.15) Admission TIMP-2 × IGFBP7≥ 0.36 1.74 (0.99–3.08) 0.053
Day 3 TIMP-2 × IGFBP7a 0.14 (0.07–0.30) 0.23 (0.10–0.61) Day 3 TIMP-2 × IGFBP7≥ 0.18 1.73 (0.93–3.22) 0.084
Outcome
Hospital RRT 2 (2.0) 6 (6.3) Treatment with RRT 3.28 (0.64–16.39) 0.137
AKI within 3 days 29 (29.3) 59 (61.5) Presence of AKI 3.85 (2.12–6.94) <0.001
Dead at 6 months 0 (0.0) 88 (91.7) Death n.a.
aData from some patients are missing
Categorical data are presented as number (percent), continuous data with skewed distribution as median (interquartile range), and continuous data with normal
distribution or mean (± standard deviation)
Presented p values are from univariate Pearson’s Chi square analysis
AKI acute kidney injury, B whole blood, BE base excess, CA cardiac arrest, CI confidence interval, CPR cardiopulmonary resuscitation, HCO3
– bicarbonate, IGFBP7
insulin-like growth factor-binding protein 7, n.a. not applicable, NGAL neutrophil gelatinase-associated lipocalin, OR odds ratio, PNO poor neurological outcome
defined as cerebral performance category 3–5, ROSC return of spontaneous circulation, RRT renal replacement therapy, S serum, SAPS simplified acute physiology
score, SOFA sequential organ failure assessment, TIMP-2 tissue inhibitor of metalloproteinase 2, VF/VT ventricular fibrillation/ventricular tachycardia
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recovery and mortality in general ICU patients [25, 28, 29].
Although data from CA patients are sparse, one recent
study revealed that NGAL measured in blood within 4 h
after ROSC was a predictor of mortality and neurological
outcome [15]. In another study, enrolment serum NGAL
concentrations in CA patients predicted mortality better
than neuron-specific enolase and S100B [14]. In agreement
with these findings, we found that urine cystatin C and
NGAL, but not urine TIMP-2 × IGFBP7, were statisti-
cally associated with mortality and PNO. We might
hypothesize that cystatin C and NGAL are influenced
by whole-body ischemia and reperfusion injuries, whereas
TIMP-2 and IGFBP7 may be more kidney-specific
markers.
Several models to predict outcome after CA have been
developed [14, 30], and addition of biomarker levels to
clinical parameters have been suggested in order to im-
prove the ability to predict [14, 31]. Although we found
that urine cystatin C and NGAL levels on admission
were risk factors of mortality and PNO, their AKI pre-
dictive accuracy was limited, and the prediction was not
uniformly improved by adding biomarker concentrations
to the clinical parameters. We therefore consider that
these predictive models cannot be used in treatment al-
location of patients, as no model had a perfect discrim-
inating ability. This is in agreement with the European
guidelines for post-resuscitation care that recommends a
multimodal strategy with prolonged observation in cases
with uncertain outcome [32]. However, the biomarkers
might be useful in clinical research involving risk stratifi-
cation of patients.
The present study has several important limitations.
No “gold-standard” definition of AKI exists, and the oc-
currence of AKI in our study was not strictly according
to the KDIGO criteria since we only assessed the first
3 days, and lacked data on body weight in 29 patients.
There are also limitations in the measurement of urine
biomarkers. Since time of urine sampling was not fully
standardized, the variation in the time from CA and
ROSC to urine sampling will affect biomarker concentra-
tions. The urine collected as spot samples at admission
and could potentially be diluted with urine present in the
urinary bladder prior to arrest. This might affect the mea-
sured concentrations of biomarkers in our study, and peak
values are most likely missed. Moreover, the urine was
stored in a refrigerator longer than recommended (i.e.,
24 h) and was centrifuged later than recommended (i.e.,
before freezing). However, as previous studies have re-
vealed a good stability of AKI biomarkers independent of
storage time [33, 34] and timing of centrifugation [33,
34], we consider the results to be valid. We also per-
formed a pilot study in 10 ICU patients with and without
AKI confirming the stability of urine cystatin C, NGAL,
and TIMP-2 × IGFBP7 [21]. Furthermore, we were unable
to compare the predictive ability of biomarkers at admis-
sion and day 3 since we did not have urine samples from
day 3 in 31 patients. We were also unable to include time
to ROSC in the multivariate analyses because data were
missing in 37 patients; this might be an important co-
variate among others not included in our analyses since
time to ROSC is a strong predictor of PNO in most stud-
ies [32, 35, 36]. Additionally, we have not controlled for
the development of AKI when assessing the ability of bio-
markers to predict mortality and PNO. Finally, our study
had a limited sample size and might also have restricted
external validity.
Strengths of the study are that all patients came from
the same cohort and time period and were treated accord-
ing to a standardized treatment protocol documenting
good and stable outcome over time [35, 37, 38]. We had
clear definitions of risk factors and outcome variables, and
tested the biomarkers in a population with a high pre-test
probability of the considered outcomes.
Conclusions
In this observational study of resuscitated comatose
OHCA patients, urine cystatin C and NGAL levels at ad-
mission and day 3 were independent risk factors for AKI,
mortality, and PNO. In contrast, TIMP-2 × IGFBP7 levels
only predicted AKI in urine samples collected at admis-
sion. Urine cystatin C and NGAL seem to be promising
biomarkers that should be explored in future studies, but
there are clear limitations in their clinical utility.
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